Proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency obesity

DBCOND0149417Gastrointestinal Gastrointestinal Tract Disorders

Proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency obesity is the indication for 1 drug in DrugBank. It is covered by 2 curated, structured indications.

Also known as: PCSK1 Deficiency Obesity
Classified under: Gastrointestinal
Gastrointestinal Tract Disorders
Gross Bleeding/Perforation
Growth and Development
Investigations
Non-site specific gastrointestinal haemorrhages
Nutritional and Metabolic Diseases
Physical Examination
Signs, Symptoms, and General Pathologies
Vascular haemorrhagic disorders
Indicated drugs: Setmelanotide

What you can answer from here — as of November 08, 2026

1Indicated drugWith each drug's targets and mechanism

Listed above

2Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

2Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for Proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency obesity share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account